BSEM

BioStem Technologies Inc

3.07

Aug 13 • 11:28 AM ET -0.73 (-19.14%)

Healthcare Biotechnology USA Micro NASD

Aug 12, 6:15 PMBioStem Q2 2026 EPS -$0.52 misses, revenue $7.9M beats estimates as company raises 2026 revenue guidance on hospital growth

Scroll to Statements

Index	-
Market Cap	54.79M
Enterprise Value	44.37M
Income	-19.88M
Sales	75.98M
Book/sh	1.88
Cash/sh	0.77
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Oct 17, 2003

P/E	-
Forward P/E	-
PEG	-
P/S	0.72
P/B	1.64
P/C	4.00
P/FCF	29.62
EV/EBITDA	-
EV/Sales	0.58
Quick Ratio	0.95
Current Ratio	1.14
Debt/Eq	0.10
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.19
EPS next Y	-0.25
EPS next Q	-0.46
EPS this Y	-400.00%
EPS next Y	87.18%
EPS next 5Y	-
EPS past 3/5Y	14.56% -7.36%
Sales past 3/5Y	90.44% 81.44%
EPS Y/Y TTM	-158.58%
Sales Y/Y TTM	-77.14%
EPS Q/Q	-406.62%
Sales Q/Q	-91.54%
Earnings	Aug 12 AMC
EPS/Sales Surpr.	-4.00% 24.36%

Insider Own	29.66%
Insider Trans	0.00%
Inst Own	-
Inst Trans	-
ROA	-19.46%
ROE	-50.09%
ROIC	-62.31%
Gross Margin	93.06%
Oper. Margin	-19.51%
Profit Margin	-26.17%
SMA20	-15.22%
SMA50	-15.97%
SMA200	-31.88%
Trades

Shs Outstand	16.97M
Shs Float	12.54M
Short Float	3.12%
Short Ratio	6.53
Short Interest	0.39M
52W High	10.71 -71.31%
52W Low	3.01 2.09%
Volatility	19.38% 12.81%
ATR (14)	0.53
RSI (14)	40.69
Beta	0.27
Rel Volume	26.88
Avg Volume	60.02K
Volume	544,445

Perf Week	-23.56%
Perf Month	-19.32%
Perf Quarter	-39.45%
Perf Half Y	-44.13%
Perf YTD	-19.35%
Perf Year	-71.22%
Perf 3Y	75.59%
Perf 5Y	187.18%
Perf 10Y	-77.89%
Recom	1.00
Target Price	7.00
Prev Close	3.80
Price	3.07
Change %	-19.14%

Today 01:03AM	BioStem Technologies Inc (BSEM) (Q2 2026) Earnings Call Highlights: Revenue Surges to $7. ... (GuruFocus.com) -19.14%
Aug-11-26 09:25AM	BioStem Technologies Inc (BSEM) Q2 2026 Earnings Report Preview: What To Expect (GuruFocus.com)
Jun-09-26 10:50AM	BioStem Technologies Expands Board with Three Appointments as Nasdaq Uplisting Remains a Key Objective (BSEM) (InvestorsHub)

BioStem Technologies, Inc. engages in the provision of regenerative medicine and anti-aging solutions. It offers pre-treatment assessment, cell therapies, anti-aging, and wellness compounds. The company was founded by Andrew Smith Van Vurst, Henry W. Van Vurst IV, and Jason Matuszewski on April 29, 1939 and is headquartered in Pompano Beach, FL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BSEM

BioStem Technologies Inc

Upgrade your Finviz experience